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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To compare the effects of targeted agents in the systemic therapy of people with metastatic renal cell carcinoma.
B A C K G R O U N D
Description of the condition
Renal cell carcinoma (RCC) incidence represents about 2.4% of
all invasive cancers and has a projected 2012 population age-stan-
dardised mortality rate of 1.8 per hundred thousand worldwide
and in the USA (GLOBOCAN 2012; Howlader 2017). Two-
thirds of cases occur in men. These figures include both renal cell
carcinoma and the less common urothelial carcinoma of the renal
pelvis; the latter is biologically related to bladder cancer and not
further considered here. Renal cell carcinoma is divided into dif-
ferent pathologic subtypes, of which the clear cell subtype repre-
sents about 75% (Srigley 2013). The more uncommon subtypes
are collectively referred to by clinicians as non-clear renal cell car-
cinomas which respond differently to treatment as compared to
clear cell renal cell carcinoma (Fernández-Pello 2017). Death from
renal cell carcinoma is usually from metastases, either detected
during staging of newly-diagnosed patients (Stage IV) or detected
during follow-up after nephrectomy. A minority of patients are
diagnosed with locally advanced disease which is too advanced for
surgical resection but without metastatic findings. The term ’ad-
vanced renal cell carcinoma’ has been used by authors to include
both metastatic and locally advanced disease that have aspects that
require separate consideration.
There has been great interest in finding more effective treatments
for metastatic renal cell carcinoma. The search for specific targets
for therapy goes back at least to Paul Ehrlich’s “magic bullet” over a
century ago (Strebhardt 2008). This concept has recently received
an enormous boost with the knowledge explosion of molecular
targets and the potential for associated therapies that are target-
specific and thereforemight have greater efficacywith less toxicity (
Sawyers 2004).Clinical proof of concept camewith the remarkable
success of single-agent imatinib for chronic myeloid leukaemia
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(Deininger 2005). Here we review the subsequent development
of targeted therapy for metastatic renal cell carcinoma.
Description of the intervention
Prior to the development of targeted agents, renal cell carcinoma
was one of the most drug-resistant malignancies. Hormonal and
cytotoxic chemotherapy agents have not been demonstrated to
improve overall survival for this condition, and remissions with
those agents occur at a frequency similar to that seen with no
therapy or with placebo (Gleave 1998; Oliver 1989). Until the
past decade, immunotherapy was the main focus of the search
for an effective drug therapy for renal cell carcinoma and was the
main initial comparator for targeted therapy; it is the subject of
a companion Cochrane Review (Coppin 2004), currently being
updated. In summary, classic immunotherapy, e.g. interferon-al-
pha or interleukin-2, has been associated with very modest sur-
vival benefit at best. When targeted agents were first being evalu-
ated, the immunotherapy agent interferon-alpha was considered
the standard comparator for first-line therapy of metastatic renal
cell carcinoma (Mickisch 2003;Motzer 2002); placebo-controlled
trials have been appropriate in the second-line setting. One should
be aware that the distribution of prognostic risk strata in clinical
trials is changing to a more favourable profile, such that direct
comparisons of interventions through head-to-head clinical trials
remain essential (Patil 2010).
Molecular pathways with multiple targets that are of particu-
lar interest in renal cell carcinoma currently fall into two major
groups: angiogenesis (Rini 2005), and intracellular signal trans-
duction pathways (Adjei 2005). The presence of a target may or
may not translate into benefit from a targeted agent (Bergsland
2006). Some agents have activity against multiple targets. Classic
immunotherapies such as interferon-alpha may have anti-angio-
genic activity but are considered a separate class of agent (Coppin
2004). Suitably large randomised controlled trials have a high fi-
nancial and resource cost, so that selection of agents for Phase III
testing requires strategic decision-making (Roberts 2003).
A recent new class of drugs has been introduced into the treatment
paradigm of clear cell RCC (Motzer 2015). Immune checkpoint
inhibitors are a new type of targeted immunotherapy and have
been very successfully tested in other immunogenic tumours such
as melanoma.
Since neither multikinase inhibitors nor immune checkpoint in-
hibitors are necessarily cytotoxic, it is possible that tumour shrink-
age may not be a reliable indicator of drug activity (Stadler 2006);
for example, objective stabilisation of previously progressive dis-
ease might result in extension of overall survival. This is especially
the case for immune checkpoint inhibition which in second-line
RCC treatment leads to prolonged overall survival without benefit
in progression-free survival.
Drug therapy formetastatic renal cell carcinoma has yet to demon-
strate curative potential. Improvement in overall survival is the
preferred and definitive outcome of interest to patients, and is
a realistic outcome if there is only one effective intervention for
an incurable cancer, as was the situation for metastatic renal cell
carcinoma at the beginning of the targeted era (i.e. from 2000
onwards). However, when participants with progressive cancer in
one arm of a randomised trial are permitted cross-over to the other
arm, as is commonly done for ethical reasons or to enhance recruit-
ment, then any survival benefit (or detriment) of the investiga-
tional agent might be obscured; the same problem might happen
if sequential active therapies are applied. For these reasons and as
in other cancer sites, the duration of freedom from cancer progres-
sion may be accepted by regulatory bodies as adequate evidence
of benefit for drug approval purposes (Johnson 2011). Surrogate
endpoints such as progression-free survival should preferably be
accompanied by patient-reported outcomes.
How the intervention might work
Molecular analysis of renal cell carcinoma has shown that this
cancer is not a homogeneous condition (Hacker 2010; Linehan
2005). A high proportion of sporadic clear cell renal cell carcino-
mas have biallelic abnormalities of the Von Hippel-Lindau (VHL)
tumour-suppressor gene (Young 2009), whereas other subtypes do
not. Absence of the active VHL gene produces results in unreg-
ulated activation of the hypoxia-inducible system and accumula-
tion of growth factors such as vascular endothelial growth factor
(VEGF). In subtypes such as papillary and chromophobe RCC
other pathways such as MET proto-oncogene (MET) and tuber-
ous sclerosis (TSC) alterations have been identified through inves-
tigation of hereditary and sporadic forms. Therefore themainstays
of first-line therapy until now are multikinase inhibitors targeting
predominantly the VEGF-receptor kinases but other targets are
included to various degrees, such as MET, AXL receptor tyrosine
kinase (AXL), platelet derived growth factor receptor (PDGFR)
and epidermal growth factor receptor (EGFR). Immune check-
point inhibitors targeting the programmed death-ligand (PD-L1)
or its receptor (PD-1) have been tested successfully in second- and
third-line treatments after failure of one or two lines of VEGFR-
targeting therapies (Motzer 2015). These drugs counteract the
tumour-driven inhibition of T-cell receptor-mediated activation
of IL-2 production and T-cell proliferation which leads to a suc-
cessful anti-tumour T-cell mediated immune activity. Currently,
these drugs are tested in first-line trials in combination with ei-
ther multikinase inhibitors or other monoclonal antibodies target-
ing circulating VEGF or anti-CTLA4 against the current first-line
monotherapy with VEGFR-targeted therapies. With more treat-
ment options being approved and investigated, it will be necessary
to distinguish the impact of therapy on different molecularly-de-
fined tumour types as well as on tumours which have been treated
with previous lines of therapy to better select patients for a given
drug based on their predicted outcome. Although available, the
necessary technology is not yet used in clinical routine. Themolec-
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ular complexities of both the disease (renal cell carcinoma) and
the treatment (targeted therapy) are resulting in a rapidly-evolving
and exciting phase in the history of the treatment of metastatic
disease. According to Uzzo 2003, “an understanding of the ba-
sic biology of renal cell carcinoma is more advanced than that of
any other solid malignancy”. Further molecular subclassification
within clear cell renal cell carcinoma may well become feasible
(Kaelin 2008).
Why it is important to do this review
The topic of this review is now the main systemic therapy of an
important type of malignancy, metastatic renal cell carcinoma, for
which the therapy has changed greatly over the past decade and
continues to be a strong focus of development of new agents and
comparative studies. This review is needed to provide an objective
and up-to-date resource for researchers, clinicians and consumers.
This will be an update of aCochrane reviewfirst published in 2008
and previously updated in 2011 (Coppin 2008; Coppin 2011).
Since the last date of full literature search, a number of additional
studies have been published and there is an evolving shift to using
previously validated targeted agents as the comparator rather than
placebo, quasi-placebo such as hormone therapy, or immunother-
apy such as interferon-alpha. There is also increasing emphasis on
second-line therapy now that targeted agents are established for
first-line therapy of metastatic renal cell carcinoma. In addition,
new agents such as immune checkpoint inhibitors are increasingly
being compared against first-line standard therapies (Kuusk 2017).
This updated protocol reflects a restriction of scope in order to fo-
cus on metastatic renal cell carcinoma within the broader category
of ’advanced disease’ that additionally included locally-advanced
cancers without metastases. The main reason for this change of
scope is because the management of locally-advanced disease may
include both systemic and surgical interventions, and therefore the
complex interaction between the two modalities as well as addi-
tional outcomes such as resectability and local control rates. Other
reasons include lack of criteria for inoperability that include both
cancer and patient factors, and the possibility that drug response
to the primary tumour might be different from the response of
its metastases. This review also now reflects the development of a
collaboration between the previous Cochrane Review authorship
and the Renal Cell Carcinoma Guideline Panel of the European
Association of Urology (EAU panel). Preliminary discussions with
the EAU panel representative Thomas Lam demonstrated a high
level of overlap between the protocols of the two groups. This
protocol is designed to minimise residual differences.
O B J E C T I V E S
To compare the effects of targeted agents in the systemic therapy
of people with metastatic renal cell carcinoma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials, including randomised discontinua-
tion trials in which treatment was stopped early because of obvious
benefits or harms (Stadler 2005). Quasi-randomised trials such as
alternate allocation are eligible for consideration. We will exclude
randomised Phase I trials as well as cross-over trials, cluster-ran-
domised trials or trials of factorial design.
Types of participants
Participants are eligible: if older than 18 years of age; have
metastatic renal cell carcinoma which is histologically or patholog-
ically verified at presentation or relapse; have an Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0, 1 or 2 or
equivalent. Participants who are evaluated in second- or later lines
therapy must have had at least one prior systemic treatment. For
individuals who are analysed in first-line therapy no prior systemic
treatment is allowed.
Exclusion criteria are: the presence of symptomatic brain metas-
tases; a life expectancy of less than 12 weeks; a serious acute or
chronic illness or recent history of cardiac event.
Studies which allow solid tumours other than renal cell carcinoma
will be eligible only if participants with renal cell carcinoma are
stratified and reported separately from other tumour types.
Diagnosis should be reported using the standard criteria (e.g.
TNM-classification) valid at the time that the trial began.
All histologic subtypes of renal cell carcinoma are eligible. We will
document individuals with clear cell and non-clear cell subtypes,
and will analyse them separately if data are available.
We will exclude studies for analysis of oncological outcomes that
are designed for or include more than 20% of participants without
metastases, i.e. locally-advanced disease or unfit for nephrectomy.
However, we will include evaluation of adverse events if reported.
Types of interventions
Agents with known or presumedmolecular targets must have been
part of the therapeutic regimen of at least one study arm. Non-
specific agents considered previously are no longer eligible, as they
are of historic interest only, including ABT-510, AE-941, and car-
boxyaminoimidazole. We exclude classic immunotherapy agents,
including recombinant cytokines and their predecessors, from this
definition of targeted therapy, but they may have been included
as part of the regimen in any study arm. See Table 1 for a list of
targeted agents to be sought, although we may identify additional
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targeted agents during the search process. Studies in which main-
tenance therapy by a targeted agent was the randomised variable
will be eligible. Studies of dose or schedule of a targeted agent will
be eligible. There are no eligibility restrictions on drug route, dose,
or schedule.
We plan to investigate the following comparisons of target agents
listed in Table 1 versus control/comparator:
Intervention
• Targeted agent (a)
• Targeted agent in combination with another targeted agent
(b)
• Targeted agent in combination with cytokine (c)
• Sequencing of targeted agent A and targeted agent B (d)
Comparator
• Placebo compared to (a), (b) or (c)
• Targeted agent other than intervention compared to (a), (b)
or (c)
• Targeted agent other than intervention in combination
with cytokine or hormonal treatment or both, compared to (a),
(b) or (c)
• Cytokine(s) compared to (a), (b) or (c)
• Hormonal treatment compared to (a), (b) or (c)
• Same agent as intervention in different dose or schedule or
both, compared to (a), (b) or (c)
• Reversed sequence of targeted agent A and targeted agent B
compared to (d)
We will distinguish comparisons in first-line therapy from com-
parisons in subsequent therapy.
We will consider whether the control arm has been validated by a
prior randomised study.
Minimum duration of intervention
Minimum duration of intervention will be four weeks.
Minimum duration of follow-up
Minimumduration of follow-upwill be 12weeks.Wewill evaluate
extended follow-up periods after the trial termination only for
adverse events.
Specific exclusion criteria
Studies observing neoadjuvant or adjuvant treatment or both with
targeted agents are not eligible for analysis.
Types of outcome measures
To be eligible for inclusion, studies must assess at least one effi-
cacy outcome by allocation arm. We will examine ’quality of life’
outcomes where available, with reference to minimally important
clinical differences where known for the assessment tools used.We
will evaluate adverse events in all studies. The selection of out-
comes for GRADE assessment was based on discussions amongst
an expert panel (EAU panel) and authors of the previous review,
and reflects outcomes of importance to stakeholders including pa-




3. Serious adverse events (Grade 3 or 4)
Secondary outcomes
1. Health-related quality of life
2. Response rate
3. Minor adverse events (Grade 1 or 2)
Method and timing of outcome measurement
• Progression-free survival: time from date of randomisation
to date of clinical or radiological progression
• Overall survival: length of time from date of randomisation
that participants are still alive
• Serious adverse events: all adverse events measured at any
time that needed surgical, endoscopic, radiological or
anaesthesiological intervention, as well as any life-threatening
complications after participants received at least one treatment in
intervention or comparator groups, classified by Common
Terminology Criteria for Adverse Events (CTCAE 2009)
• Quality of life: evaluated by validated instrument such as
Supplementary Quality of Life Questionaire (SQLQ), Functional
Assessment of Cancer Therapy (FACT), Functional Assessment
of Cancer Therapy-Kidney Symptom Index (FKSI) or European
Quality of Life-5 Dimensions (EQ-5D). If they are available we
will focus on data of pre- to post-treatment evaluation
• Response rate: measured by RECIST or modified RECIST
criteria (Eisenhauer 2009)
• Minor adverse events: all adverse events measured at any
time that could be managed by observation or pharmacological
treatment after participants received at least one treatment in
intervention or comparator groups, classified by Common
Terminology Criteria for Adverse Events (CTCAE)
If time-to-event data are not available, we will try to assess the
number of events per total for dichotomised outcomes at certain
time points (e.g. at one, two, three, four, five years, or at the longest
reported follow-up).
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Main outcomes for ’Summary of findings’ table
1. Progression-free survival
2. Overall survival
3. Health-related quality of life
4. Serious adverse events
Search methods for identification of studies
Overall time frame: we will conduct a new search from 1 January
2000 (we found no earlier studies in the previous version of this
review) to an agreed cut-off date to be at least onemonth before the
date of search, to allow for indexing. We may assemble duplicate
searches from separate time segments, for example the EAU panel
has completed a search to 30 November 2012 using the algorithm
in Appendix 1, and the Canadian authors have searched to 30
June 2010 as described previously (Coppin 2008, electronically
updated to 30 June 2011 for Coppin 2011).
There will be no restriction by language or publication status.
Electronic searches
We will search the Cochrane Central Register of Controlled Tri-
als (CENTRAL), MEDLINE, Embase, and LILACS databases,
as well as trial registers ClinicalTrials.gov and the WHO
International Clinical Trials Registry Platform (apps.who.int/
trialsearch/).
We will use Review Manager 2014 as reference management soft-
ware to initially remove duplicate records.
Searching other resources
1. Handsearching of abstracts in the proceedings of the annual
meetings of the American Urological Association, the European
Cancer Conference (ECCO), the European Society of Medical
Oncology (ESMO), and the American Society of Clinical
Oncology (ASCO), all from 2000 to current year; and the
annual ASCO genitourinary meeting (2008 to current year)
2. Handsearching of the bibliographies of included primary
studies and of recent systematic reviews of targeted therapies for
metastatic or advanced renal cell carcinoma
3. We will consult clinical experts (EAU panel) to identify
additional potentially important or seminal studies which may
have been missed by the electronic searches
4. We will try to identify other potentially eligible trials or
ancillary publications by searching the reference lists of included
trials, systematic reviews, meta-analyses and health technology
assessment reports. We will also contact authors of included trials
to identify any additional information on the retrieved trials, and
to determine if further trials exist that we may have missed. We
will also search databases from regulatory agencies (European
Medicines Agency (EMA) and US Food and Drugs
Administration (FDA)) (Hart 2012; Schroll 2015).
Data collection and analysis
Selection of studies
Inclusion and exclusion of studies
Two review authors (FH, LM) will independently conduct
searches, assess full-text records, and independently map records
to potentially eligible studies for inclusion/exclusion. We will re-
solve discrepancies by discussion or by arbitration from additional
review authors (TL, AB) as necessary.
We will refer to trials by their eight-digit NCT number where
known. We will classify studies as included studies, excluded stud-
ies, studies awaiting classification, or ongoing studies, in accor-
dance with the criteria for each provided in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). We
will document the search process in a study flow diagram.
We will document reasons for exclusion of identified studies not
suitable for this review in a ’Characteristics of excluded studies’
table. We will include studies that do not report on our primary
or secondary outcomes, and will consider them for qualitative
analysis.
Data extraction and management
Two review authors (FH, LM) will independently extract data
using an agreed template, which we will pilot, and will resolve
any discrepancies by consensus, with recourse to a third review
author (TL, AB) if needed. We will construct a master database of
consensus-agreed data, whichwill be available to all review authors.
Data extraction fields for each study will include:
1. Basic study design features (e.g. parallel-group randomised
trial);
2. Dates when the study was conducted;
3. Study setting;
4. Participant eligibility criteria and actual accrual by arm for
age, race, gender, performance status, prior nephrectomy, prior
systemic therapy, histologic subtype, and prognostic risk method
and distribution;
5. Stratification parameters, if any;
6. Detailed interventions, including criteria for discontinuing
therapy and cross-over to the investigational arm;
7. The sample size for each included study and for each
intervention/comparator group;
8. Details (such as dose, route, frequency, duration, as
applicable) of each intervention/comparator relevant to this
review;
9. Treatment delivery evaluation such as time point of
administration and masking of treatment in interventional/
comparator groups;
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10. Frequency and protocol status (e.g. planned versus later
protocol modification) of cross-over to the investigational arm;
11. Details of the outcome definition for outcomes relevant to
this review that were assessed in each study, method of outcome
measurement for each outcome, timing of outcome
measurement for each outcome, subgroups relevant to this
review that were assessed for each outcome;
12. Reported statistics for each time-dependent outcome, i.e.
hazard ratio and two-sided log rank P value;
13. All adverse events reported by allocation;
14. Study funding sources;
15. Details of declarations of interest among the trialists.
We will attempt to contact study investigators to obtain missing
data for primary outcomes for eligible studies.
We will report identified studies in a ’Characteristics of included
studies’ table. If an eligible trial is still ongoing and not reporting
any results, we will collect information in a ‘Characteristics of
ongoing studies’ table.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we will maximise the infor-
mation yield by collating all available data and will use the most
complete data set aggregated across all known publications. We
will list duplicate publications, companion documents, multiple
reports of a primary trial and trial documents of included trials
(such as trial registry information) as secondary references under
the study ID of the included trial. We will also list duplicate pub-
lications, companion documents, multiple reports of a trial and
trial documents of excluded trials (such as trial registry informa-
tion) as secondary references under the study ID of the excluded
trial.
Data from clinical trial registers
In cases where data of included trials are available as study results
in clinical trial registers such as ClinicalTrials.gov or similar re-
sources, we will make full use of this information and extract data.
If there is also a full publication of the trial, we will collate and
critically appraise all available data. If an included trial is marked
as a completed study in a clinical trial register but no additional
information (study results, publication or both) is available, we
will add this trial to the table ’Characteristics of studies awaiting
classification’.
Assessment of risk of bias in included studies
Two review authors (FH, LM) will independently use the latest
version of the Cochrane tool for assessing risk of bias to construct
a ’Risk of bias’ table for each study, resolving discrepancies by
consensus (Higgins 2011b). If needed, a third review author (TL,
AB) will be involved. We will rate the following domains at low,
high, or unclear risk of bias:
1. Random sequence generation
2. Allocation concealment
3. Blinding of participants and personnel
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective reporting
7. Other potential sources of bias.
We will assess the ’Risk of bias’ domains ’blinding of participants
and personnel’, ’blinding of outcome assessment’, and ’incomplete
outcome data’ on an outcome-specific basis, grouping subjective
outcomes and objective outcomes for the blinding domains, and
grouping outcomes according to similar completeness of data for
the outcome-specific assessments of ’incomplete outcome data’.
We regard all outcomes as susceptible to performance bias, whereas
all outcomes except for ’overall survival’ are regarded as susceptible
to detectionbias.Wewill summarise the risk of bias across domains
for each outcome in each included study. We will assess the risk of
attrition bias in three combined outcome groups that are defined
by oncological, adverse event and quality-of-life outcomes. We
will present our judgements in a ’Risk of bias’ graph and a ’Risk
of bias’ summary figure.
Measures of treatment effect
When at least two included trials are available for a comparison
and a given outcome, we will try to express dichotomous data as a
risk ratio (RR) or odds ratio (OR) with 95% confidence interval
(CI). For continuous outcomes measured on the same scale we
will estimate the intervention effect using the mean difference
(MD)with 95%CI. For continuous outcomesmeasuring the same
underlying concept but using different measurement scales, we
will calculate the standardised mean difference (SMD). We will
express time-to-event data as a hazard ratio with a 95% CI. We
will use RevMan software (Review Manager 2014) for the ’Risk
of bias’ analysis.
Unit of analysis issues
If more than one comparison from the same trial is eligible for
inclusion in the samemeta-analysis, we will either combine groups
to create a single pair-wise comparison or appropriately reduce
the sample size so that the same participants do not contribute
to multiple comparisons (splitting the ’shared’ group into two or
more groups). While the latter approach offers some solution to
adjusting the precision of the comparison, it does not account
for correlation arising from the same set of participants being in
multiple comparisons (Higgins 2011a).
Dealing with missing data
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We plan to perform intention-to-treat analyses where data are
available; however, we will not impute missing data and will oth-
erwise perform an available-case analysis. We will include stud-
ies that combine outcomes from metastatic and locally-advanced
disease in tabulations if the locally-advanced subgroup is docu-
mented as less than 20% of the total participants randomised; we
will consider other studies separately.
If possible, we will obtain missing data from the authors of the
included trials. We will carefully evaluate important numerical
data such as screened, randomly-assigned participants as well as
intention-to-treat, and as-treated and per-protocol populations.
We will investigate attrition rates (e.g. dropouts, losses to follow-
up, withdrawals), and we will critically appraise issues concerning
missing data and use of imputation methods (e.g. last observation
carried forward).
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we will not report trial results as the pooled effect estimate in
a meta-analysis. We will identify heterogeneity (inconsistency) by
visually inspecting the forest plots and by using a standard Chi2
test with a significance level of α = 0.1. In view of the low power
of this test, we will also consider the I2 statistic, which quantifies
inconsistency across trials, to assess the impact of heterogeneity on
themeta-analysis (Higgins 2002;Higgins 2003).We will interpret
the I2 statistic as follows:
• 0% to 40%, may not be important
• 30% to 60%, represents moderate heterogeneity
• 50% to 90%, represents substantial heterogeneity
• 75% to 100%, represents considerable heterogeneity
When we find heterogeneity, we will attempt to determine pos-
sible reasons for it by examining individual study and subgroup
characteristics.
Assessment of reporting biases
If we include 10 or more trials that investigate a particular out-
come, we will use funnel plots to assess small-trial effects. Several
explanations may account for funnel plot asymmetry, including
true heterogeneity of effect with respect to trial size, poor method-
ological design (and hence bias of small trials) and publication
bias, so we will be cautious in our interpretation of results (Sterne
2011).
Data synthesis
We plan to undertake (or display) a meta-analysis only if we judge
participants, interventions, comparisons and outcomes to be suf-
ficiently similar to ensure an answer that is clinically meaningful.
Unless good evidence shows homogeneous effects across trials, we
will primarily summarise low risk of bias data using a random-ef-
fects model (Wood 2008). We will interpret random-effects meta-
analyses with due consideration for the whole distribution of ef-
fects, ideally by presenting a prediction interval (Higgins 2009).
This specifies a predicted range for the true treatment effect in an
individual trial (Riley 2011). For rare events such as event rates
below 1% we will use the Peto odds ratio, provided that there
is no substantial imbalance between intervention and compara-
tor group sizes, and that intervention effects are not exception-
ally large. We will also perform statistical analyses according to
the statistical guidelines presented in the Cochrane Handbook for
Systematic Reviews of Interventions (Higgins 2011a).
Quality of evidence
Wewill present the overall quality of the evidence for each outcome
according to the GRADE approach, which takes into account five
criteria not only related to internal validity (risk of bias, inconsis-
tency, imprecision, publication bias), but also to external validity,
such as directness of results (Guyatt 2008). For each comparison,
two review authors (FH, LM) will independently rate the quality
of evidence for each outcome as ’high’, ’moderate’, ’low’, or ’very
low’, using GRADEpro GDT. We will resolve any discrepancies
by consensus, or, if needed by recourse to a third review author
(TL, AB). For each comparison, we will present a summary of the
evidence for the main outcomes in a ’Summary of findings’ table,
which provides key information about the best estimate of the
magnitude of the effect in relative terms and absolute differences
for each relevant comparison of alternative management strate-
gies; numbers of participants and studies addressing each impor-
tant outcome; and the rating of the overall confidence in effect
estimates for each outcome (Guyatt 2011; Schünemann 2011).
Statistical analysis
We anticipate analysis of four types of outcomes: categorical out-
comes, such as tumour remission; single time-dependant out-
comes, such as overall survival; quality-of-life surveys; and toxi-
city tables. Of these, methods for analysis of dichotomous out-
comes are fully covered by standard Cochrane procedures (Deeks
2011). We will consider multidimensional quality-of-life and tox-
icity outcomes individually. Time-dependent outcomes are poten-
tially problematic.Where only a single study is available for a com-
parison, we will accept any standard statistical analysis, such as the
log-rank test used by the author, but we will prefer the hazard ratio
and log-rank testing. For meta-analysis of multiple studies of the
same type, we will use extraction of a dichotomous endpoint such
as survival at one year from randomisation (see also Measures of
treatment effect above).
Subgroup analysis and investigation of heterogeneity
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We plan to perform a subgroup analysis if data are available for
the following:
1. Nephrectomy done or not done prior to treatment
2. ECOG performance status (0,1 or 2)
3. Clear cell versus non-clear cell renal cell carcinoma
Sensitivity analysis
We plan sensitivity analysis for studies that are at a high risk of
bias for sequence generation, allocation concealment and blinding
versus studies at low risk of bias. We will conduct a separate meta-
analysis for validation of results studies at low risk of bias only.
Summary of findings table
We will create the ’Summary of findings’ table based on the meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions bymeans of RevMan’s tables editor (ReviewManager
2014). We will include an appendix entitled ’A checklist to aid
consistency and reproducibility of GRADE assessments’, devel-
oped by Meader 2014 to help with standardisation of the ’Sum-
mary of findings’ tables (Higgins 2011a). Alternatively, we will
use the GRADEpro Guideline Development Tool (GDT) soft-
ware (GRADEpro GDT) and present evidence profile tables as an
appendix. We will present results for the outcomes as described
in the Types of outcome measures section. If meta-analysis is not
possible, we will present the results in a narrative format in the
’Summary of findings’ table. We will justify all decisions to down-
grade the quality of trials using footnotes, and we will make com-
ments to aid the reader’s understanding of the Cochrane Review
where necessary.
A C K N OW L E D G E M E N T S
We thank Cochrane Urology Review Group representatives Alea
Miller and PhilippDahm, for facilitating this collaboration and for
editorial suggestions, and Molly M Neuberger, for administrative
assistance. We wish to acknowledge additional authors contribut-
ing to previous versions of this review, Chris Coppin (Canada),
Christian Kollmannsberger (Canada), Lyly Le (Canada), Franz
Porzsolt (Germany), and Timothy J Wilt (USA). We also thank
all members of the EAU Renal Cell Cancer Guideline Panel for
support and individual contributions.
R E F E R E N C E S
Additional references
Adjei 2005
Adjei AA, Hidalgo M. Intracellular signal transduction
pathway proteins as targets for cancer therapy. Journal of
Clinical Oncology 2005;23(23):5386–403.
Bergsland 2006
Bergsland EK. When does the presence of the target predict
response to the targeted agent?. Journal of Clinical Oncology
2006;24(2):213–6.
Coppin 2004
Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman
A, Wilt T. Immunotherapy for advanced renal cell cancer.
Cochrane Database of Systematic Reviews 2004, Issue 3.
[DOI: 10.1002/14651858.CD001425.pub2]
CTCAE 2009
National Cancer Institute. Common Terminology Criteria
for Adverse Events v4.0. NCI, NIH, DHHS May 29th
2009:09–7473.
Deeks 2011
Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 9:
Analysing data and undertaking meta-analyses. In: Higgins
JPT, Green S, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Deininger 2005
Deininger M, Buchdunger E, Druker BJ. The development
of imatinib as a therapeutic agent for chronic myeloid
leukemia. Blood 2005;105(7):2640–53.
Eisenhauer 2009
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH,
Sargent D, Ford R, et al. New response evaluation criteria
in solid tumours: revised RECIST guideline (version 1.1).
European Journal of Cancer 2009;45(2):228–47.
Fernández-Pello 2017
Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam
TB, Albiges L, et al. A systematic review and meta-analysis
comparing the effectiveness and adverse effects of different
systemic treatments for non-clear cell renal cell carcinoma.
European Urology 2017;71(3):426–43.
Gleave 1998
Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad
F, et al. Interferon gamma-1b compared with placebo in
metastatic renal-cell carcinoma. New England Journal of
Medicine 1998;338(18):1265–71.
GLOBOCAN 2012
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S,
Mathers C, et al. Globocan 2012: Estimated Cancer
Incidence, Mortality and Prevalence Worldwide 2012.
Available from globocan.iarc.fr (accessed 16 March 2015).
8Targeted therapy for metastatic renal cell carcinoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
GRADEpro GDT [Computer program]
Evidence Prime Inc. GRADEpro GDT: GRADEpro
Guideline Development Tool. McMaster University, 2015.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y,
Alonso-Coello P, et al. GRADE: an emerging consensus on
rating quality of evidence and strength of recommendations.
BMJ (Clinical Research Ed.) 2008;336(7650):924–6.
Guyatt 2011
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek
J, et al. GRADE guidelines: 1. Introduction-GRADE
evidence profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94.
Hacker 2010
Hacker KE, Rathmell WK. Emerging molecular
classification in renal cell carcinoma: implications for drug
development. Targeted Oncology 2010;5(2):75–84.
Hart 2012
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-
analyses of drug trials: reanalysis of meta-analyses. BMJ
2012;344:d7202.
Higgins 2002
Higgins JPT, Thompson SG. Quantifying heterogeneity
in a meta-analysis. Statistics in Medicine 2002;21(11):
1539–58. [DOI: 10.1002/sim.1186]
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ (Clinical
Research Ed.) 2003;327(7414):557–60. [DOI: 10.1136/
bmj.327.7414.557]
Higgins 2009
Higgins JP, Thompson SG, Spiegelhalter DJ. A re-
evaluation of random-effects meta-analysis. Journal of the
Royal Statistical Society. Series A, (Statistics in Society) 2009;
172(1):137–59.
Higgins 2011a
Higgins JPT, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from www.handbook.cochrane.org.
Higgins 2011b
Higgins JPT, Altman DG, Sterne JAC, editor(s). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Green S, editor(s). Cochrane Handbook for Systematic
Reviews of Interventions Version 5.1.0 (updated March
2011). The Cochrane Collaboration, 2011. Available from
www.handbook.cochrane.org.
Howlader 2017
Howlader N, Noone AM, Krapcho M, Miller D, Bishop
K, Kosary CL, et al (eds). SEER Cancer Statistics
Review, 1975-2014. National Cancer Institute. Bethesda,
MD, posted to the SEER web site, April 2017; Vol.
seer.cancer.gov/csr/1975_2014/, based on November 2016
SEER data submission.
Johnson 2011
Johnson JR, Ning Y-M, Farrell A, Justice R, Keegan P,
Pazdur R. Accelerated approval of oncology products: the
Food and Drug Adminstration experience. Journal of the
National Cancer Institute 2011;103(8):636–44.
Kaelin 2008
Kaelin WG Jr. Kidney cancer: now available in a new
flavor. Cancer Cell 2008;14(6):423–4.
Kuusk 2017
Kuusk T, Albiges L, Escudier B, Grivas N, Haanen J, Powles
T, et al. Antiangiogenic therapy combined with immune
checkpoint blockade in renal cancer. Angiogenesis 2017;20
(2):205.
Linehan 2005
Linehan WM, Grubb RL, Coleman JA, Zbar B, Walther
MM. The genetic basis of cancer of kidney cancer:
implications for gene-specific clinical management. BJU
International 2005;95 Suppl 2:2–7.
Meader 2014
Meader N, King K, Llewellyn A, Norman G, Brown J,
Rodgers M, et al. A checklist designed to aid consistency
and reproducibility of GRADE assessments: development
and pilot validation. Systematic Reviews 2014;3:82. [DOI:
10.1186/2046-4053-3-82]
Mickisch 2003
Mickisch GHJ. Rational selection of a control arm for
randomised trials in metastatic renal cell carcinoma.
European Urology 2003;43(6):670–9.
Motzer 2002
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M.
Interferon-alfa as a comparative treatment for clinical trials
of new therapies against advanced renal cell carcinoma.
Journal of Clinical Oncology 2002;20(1):289–96.
Motzer 2015
Motzer RJ, Escudier B, McDermott DF, George S,
Hammers HJ, Srinivas S, et al. Nivolumab versus
everolimus in advanced renal-cell carcinoma. New England
Journal of Medicine 2015;373:1803–13.
Oliver 1989
Oliver RTD, Nethersell ABW, Bottomly JM. Unexplained
spontaneous regression and alpha-interferon as treatment
for metastatic renal carcinoma. British Journal of Urology
1989;63(2):128–31.
Patil 2010
Patil S, Ishill N, Deluca J, Motzer RJ. Stage migration and
increasing proportion of favorable-prognosis metastatic
renal cell carcinoma patients. Cancer 2010;116(2):347–54.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Riley 2011
Riley RD, Higgins JP, Deeks JJ. Interpretation of random
effects meta-analyses. BMJ 2011;342:d549.
9Targeted therapy for metastatic renal cell carcinoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rini 2005
Rini BI, Small EJ. Biology and clinical development of
vascular endothelial growth factor-targeted therapy in renal
cell carcinoma. Journal of Clinical Oncology 2005;23(5):
1028–43.
Roberts 2003
Roberts TG Jr, Lynch TJ Jr, Chabner BA. The phase III
trial in the era of targeted therapy: unravelling the “go or
no go” decision. Journal of Clinical Oncology 2003;21(19):
3683–95.
Sawyers 2004
Sawyers C. Targeted cancer therapy. Nature 2004;432
(7015):294–7.
Schroll 2015
Schroll JB, Bero L. Regulatory agencies hold the key
to improving Cochrane Reviews of drugs [editorial].
Cochrane Database of Systematic Reviews 2015;4:10:1002/
14651858.ED000098.
Schünemann 2011
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE,
Glasziou P, Guyatt GH. Chapter 11: Presenting results
and ‘Summary of findings’ tables. In: Higgins JPT, Green
S, editor(s), Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011).
The Cochrane Collaboration, 2011. Available from www.
handbook.cochrane.org.
Srigley 2013
Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI,
Grignon D, et al. The International Society of Urological
Pathology (ISUP) Vancouver Classification of Renal
Neoplasia. American Journal of Surgical Pathology 2013;37
(10):1469–89.
Stadler 2005
Stadler W, Rosner G, Small E, Hollis D, Rini B, Zaentz
SD, et al. Successful implementation of the randomized
discontinuation trial design: an application to the study of
the putative antiangiogenic agent carboxyaminoimdazole -
CALBG 69901. Journal of Clinical Oncology 2005;23(16):
3726–32.
Stadler 2006
Stadler WM. New targets, therapies, and toxicities: lessons
to be learned. Journal of Clinical Oncology 2006;24(1):4–5.
Sterne 2011
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau
J, et al. Recommendations for examining and interpreting
funnel plot asymmetry in meta-analyses of randomised
controlled trials. BMJ 2011;343:d4002.
Strebhardt 2008
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept:
100 years of progress. Nature Reviews Cancer 2008;8(6):
473–80.
Uzzo 2003
Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N,
Greenberg RE, et al. The basic biology and immunobiology
of renal cell carcinoma: considerations for the clinician.
Urologic Clinics of North America 2003;30(3):423–36.
Wood 2008
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman
DG, et al. Empirical evidence of bias in treatment effect
estimates in controlled trials with different interventions
and outcomes: meta-epidemiological study. BMJ 2008;15;
336(7644):601–5.
Young 2009
Young AC, Craven RA, Cohen D, Taylor C, Booth C,
Harnden P, et al. Analysis of VHL gene alterations and their
relationship to clinical parameters in sporadic conventional
renal cell carcinoma. Clinical Cancer Research 2009;15(24):
7582–92.
References to other published versions of this review
Coppin 2006
Coppin C, Porzolt F, Le L, Autenrieth M, Wilt T. Targeted
therapy for advanced renal cell carcinoma. Cochrane
Database of Systematic Reviews 2006, Issue 1. [DOI:
10.1002/14651858.CD006017]
Coppin 2008
Coppin C, Le L, Wilt TJ, Kollmannsberger C. Targeted
therapy for advanced renal cell carcinoma. Cochrane
Database of Systematic Reviews 2008, Issue 2. [DOI:
10.1002/14651858.CD006017.pub2]
Coppin 2011
Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.
Targeted therapy for advanced renal cell cancer (RCC): a
Cochrane systematic review of published randomised trials.
BJU International 2011;108(10):1556–63.
∗ Indicates the major publication for the study
10Targeted therapy for metastatic renal cell carcinoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S













Other agents identified during search
A P P E N D I C E S
Appendix 1. EAU panel search strategy
Courtesy of the EAU panel, reproduced with permission.
MEDLINE 1946 to November week 3 2014
MEDLINE-In-Process and other Non-Indexed Citations December 11 2014
1. randomized controlled trial.pt.








11Targeted therapy for metastatic renal cell carcinoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10. Carcinoma, Renal Cell/
11. (metastas* adj5 ((kidney or renal) adj2 (cancer* or carcinoma* or neoplasm* or tum?or* or mass*))).tw.
12. or/10-11
13. Chemotherapy, Cancer, Regional Perfusion/
14. thalidomide/
15. exp Antineoplastic Protocols/
16. exp Antineoplastic agents/
17. (axitinib or bevacizumab or dovitinib or erlotinib or everolimus or lapatinib or pazapanib or sorafenib or sunitinib or temsirolimus
or thalidomide or tivozanib).tw.
18. antineoplastic$.tw.
19. or/13-18
20. 9 and 12 and 19
21. (conference or letter or editorial or comment*).pt.
22. exp animals/ not humans/
23. 20 not (21 or 22)
24. Limit 23 to yr=“2001 -Current”
Embase 1974 to 2014 December 22
1. kidney carcinoma/
2. (metastas* adj5 ((kidney or renal) adj2 (cancer* or carcinoma* or neoplasm* or tum?or* or mass*))).tw.
3. 1 or 2
4. exp cancer chemotherapy/













18. (axitinib or bevacizumab or dovitinib or erlotinib or everolimus or lapatinib or pazapanib or sorafenib or sunitinib or temsirolimus







25. 3 and 20 and 24
26. exp animals/ not humans/
27. (conference or letter or editorial or comment*).pt.
28. 25 not (26 or 27)
29. Limit 28 to yr=“2001 -Current”
Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials
(The Cochrane Library, Issue 11 of 12, November 2014) www.thecochranelibrary.com
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1. MeSH descriptor Carcinoma, Renal Cell, this term only
2. (metastas* near/5 ((kidney or renal) near/2 (cancer* or carcinoma* or neoplasm* or tum?or* or mass*)))
3. (#1 OR #2)




(tw:(renal cell carcinoma or renal cancer or renal tumour$ or renal tumor$ or renal carcinoma$ or renal neoplasm$ or renal mass$ or
kidney cancer or kidney tumour$ or kidney tumor$ or kidney neoplasm$ or kidney mass$)) OR (mh:(kidney neoplasms))
Type of study: Controlled Clinical Trial
Clinicaltrials.gov: http://clinicaltrials.gov
Basic search: metastatic renal cell carcinoma
WHO International Clinical Trials Registry Platform http://apps.who.int/
Basic search: metastatic renal cell carcinoma
H I S T O R Y
Protocol first published: Issue 9, 2017
Date Event Description
1 July 2010 New search has been performed Complete update with additional studies, revised anal-
ysis, risk of bias assessment, and revised conclusions.
Specifically, the search has been updated from the end of
2007 to June 2010, with 5 new eligible studies identified;
analyses are now based on the nature of the control arm.
Targeted agents have now been validated as first and sec-
ond-line therapy choices for patients with advanced renal
cancers of the clear cell subtype
8 April 2010 New search has been performed Converted to new review format.
14 January 2008 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
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To be decided after discussion and consensus
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External sources
• No sources of support supplied
N O T E S
This is a protocol for a Cochrane Review that will serve to update and replace the existing Cochrane Review entitled, “Targeted therapy
for advanced renal cell carcinoma” (Coppin 2008).
We have based parts of the Methods section of this Cochrane protocol on a standard template established by the CMED Group.
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